BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TC-5619: Phase IIb started

Targacept began a double-blind, placebo-controlled, international Phase IIb trial to evaluate 5 and 50 mg once-daily oral TC-5619 for 24 weeks in about 450 patients with...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >